Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Resistance Training × Genitourinary × Clear all

Phase

Phase NA 9 Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1 Other neoplasm 1 Other hematologic neoplasm 1 Other 1 Lymphoid 1 Head & Neck 1 Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 168 Gemcitabine 126 Prednisone 125 pembrolizumab 102 enzalutamide 100 Abiraterone Acetate 92 Nivolumab 86 Magnetic Resonance Spectroscopy 86 Cisplatin 86 Leuprolide 81 Radiotherapy 79 Sunitinib 77 Carboplatin 73 Specimen Handling 61 Radiosurgery 56 Paclitaxel 54 Goserelin 53 Androgen Antagonists 50 bicalutamide 49 Ipilimumab 49 apalutamide 47 Bevacizumab 44 Sorafenib 43 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 42 cabozantinib 40 cabazitaxel 40 Everolimus 40 abiraterone 39 atezolizumab 35 Axitinib 35

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06271551 2024-02-21

ESTRACISE

Central Finland Hospital District

Phase 2 Not yet recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡